Inhibition of the epidermal growth factor receptor ( EGFR ) with monoclonal antibodies or small-molecule inhibitors of the tyrosine kinase ( TK ) domain of the receptor have demonstrated modest , albeit significant , antitumor activities in patients with non-small-cell lung cancer ( NSCLC ) .